{"entity":{"id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","aka":[],"tldr":"A phase 3 trial testing QL1706 in non-small-cell lung cancer, now recruiting.","summary":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection is a phase 3 interventional study registered as NCT05487391, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomised, Double-blind, Multicenter Phase III Clinical Study. Planned enrolment is 632 participants (estimated). The study started in 2022-12-08 and primary completion is expected in 2027-08-31. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05487391","url":"https://clinicaltrials.gov/study/NCT05487391"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ql1706"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05487391","phase":"3","setting":"QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomized, Double-blind, Multicenter Phase III Clinical Study","sponsor":"Qilu Pharmaceutical","participation":[{"nct":"NCT05487391","source":"https://clinicaltrials.gov/study/NCT05487391","fetchedAt":"2026-10-07T16:53:43.406Z","studySha256":"f8badb567ccfe56ed6fed357817806318ff3f8d8bafc4cb072a2d0155f49f3f2","overallStatus":"RECRUITING","lastUpdatePosted":"2024-10-15","leadSponsor":"Qilu Pharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":632,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2022-12-08","startedType":"actual","enrolled":632,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05487391/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"drug":[{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}]}}